Heron Therapeutics (HRTX) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Heron Therapeutics (HRTX) over the last 11 years, with Q4 2024 value amounting to $17.8 million.
- Heron Therapeutics' Accumulated Depreciation & Amortization rose 480.97% to $17.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $17.8 million, marking a year-over-year increase of 480.97%. This contributed to the annual value of $17.8 million for FY2024, which is 480.97% up from last year.
- Latest data reveals that Heron Therapeutics reported Accumulated Depreciation & Amortization of $17.8 million as of Q4 2024, which was up 480.97% from $17.0 million recorded in Q4 2023.
- Heron Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $17.8 million for Q4 2024, and its period low was $10.9 million during Q4 2020.
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $14.3 million (2022), whereas its average is $14.7 million.
- In the last 5 years, Heron Therapeutics' Accumulated Depreciation & Amortization soared by 3547.66% in 2020 and then soared by 480.97% in 2024.
- Over the past 5 years, Heron Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $10.9 million in 2020, then rose by 21.81% to $13.2 million in 2021, then increased by 7.93% to $14.3 million in 2022, then grew by 19.14% to $17.0 million in 2023, then rose by 4.81% to $17.8 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $17.8 million for Q4 2024, versus $17.0 million for Q4 2023 and $14.3 million for Q4 2022.